Biotech News

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, Inc. (ETNB)89bio, Inc.Company update

SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that

Open original release

Related news

89bio, Inc.

89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biopharma
Location
United States